Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cpn10 safety study in multiple sclerosis
ACTRN12606000037505Phase 2Completed
- Sponsor
- Cbio
- Start
- Jan 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of ala-cpn10 in multiple sclerosis (MS) (3 arms), sponsored by Cbio. Primary endpoint: Adverse event profile. Started Jan 2005; status: completed.
02
Drugs
ala-cpn10
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12606000037505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000037505.